No intervention +− Core needle biopsy | |
Mastectomy or conservative surgery +/− adjuvant radiation therapy | |
Neoadjuvant chemotherapy + surgery +/− radiation therapy + anti-androgen therapy (if AR+) + anti-HER2 antibodies (if HER2+) +/− PI3 kinase inhibition and CDK4/6 inhibitors (if biomarkers detected) |
100% strictly match to AR (+,) ER(−), PR (−) criteria | >90% | AR pathway | |
1/3 positive, 2/3 negative | 47.1% | HER2 signaling pathway | |
75% | 96.4% | AR pathway | |
> 90% | > 90% | Oxidative degradation pathways | |
94.7% | 94.7% (classified with pure apocrine carcinoma) | MAPK/ERK signaling pathway EGFR/Src/ERK signaling pathway | |
>80% | 100% | PI3K/mTOR pathway | |
46–50% | 61.8% | PI3K/mTOR/p53 pathway | |
10–40% | N/A | PD-1/PD-L1 pathway | |
57% | N/A | AR pathway |